|US: Pfizer to End Lipitor Ads by Jarvik
by STEPHANIE SAUL, The New York Times
February 26th, 2008
Under criticism that its ads are misleading, Pfizer said Monday that it would cancel a long-running advertising campaign using the artificial heart pioneer Robert Jarvik as a spokesman for its cholesterol drug Lipitor.
|CHINA: China Plant Played Role In Drug Tied to 4 Deaths
by ANNA WILDE MATHEWS and THOMAS M. BURTON, The Wall Street Journal
February 14th, 2008
A Chinese facility that hasn't been inspected by the U.S. Food and Drug Administration made the active ingredient in much of the widely used Baxter International Inc. blood-thinner that is under investigation after reports of hundreds of allergic reactions and four deaths among the drug's users, the agency said yesterday.
|US: Committee Investigates Ad Tactics for Lipitor|
by Stephanie Saul, New York Times
February 8th, 2008
A Congressional investigation revealed that Pfizer agreed to pay Dr. Jarvik $1,350,000 as a celebrity pitchman for the heart drug Lipitor, and wants to know how much stunt doubles in the ads may have also been paid.
|US: Drug Ads Raise Questions for Heart Pioneer
by STEPHANIE SAUL, The New York Times
February 7th, 2008
Celebrity advertising endorsements are nothing new, of course. But the Lipitor campaign is a rare instance of a well-known doctor’s endorsing a drug in advertising — and it has helped rekindle a smoldering debate over whether it is appropriate to aim ads for prescription drugs directly at consumers.
|CHINA: Tainted Drugs Tied to Maker of Abortion Pill
by JAKE HOOKER and WALT BOGDANICH, The New York Times
January 31st, 2008
A huge state-owned Chinese pharmaceutical company that exports to dozens of countries, including the United States, is at the center of a nationwide drug scandal after nearly 200 Chinese cancer patients were paralyzed or otherwise harmed last summer by contaminated leukemia drugs.
|US: Antidepressants Under Scrutiny Over Efficacy
by DAVID ARMSTRONG and KEITH J. WINSTEIN, Wall Street Journal
January 17th, 2008
The effectiveness of a dozen popular antidepressants has been exaggerated by selective publication of favorable results, according to a review of unpublished data submitted to the Food and Drug Administration.
|GLOBAL: Global campaign vows to fight MNC drug monopoly|
by Marwaan Macan-Markar , IPS News
November 26th, 2007
Public health and HIV/AIDS activists from the developing world are seeking to break the monopoly over drugs held by pharmaceutical giants through a new global campaign designed to influence international debate over the issue.
|US: V.A. Is Limiting Use of Diabetes Drug|
by Stephanie Saul, NY Times
October 18th, 2007
The Department of Veterans Affairs has decided to severely limit the use of Avandia, the once-popular drug for Type 2 diabetes, delivering another blow to the product’s maker, GlaxoSmithKline.
|INDIA: Novartis Patents Case Far From Dead|
by Praful Bidwai, Inter Press Service News Agency
August 9th, 2007
Cancer patients in India have reason to be relieved at a high court ruling this week which dismissed a petition by Swiss pharmaceuticals multinational corporation (MNC) Novartis challenging an Indian law which denies patents for minor or trivial improvements to known drugs.
|US: FDA Panel to Review Avandia|
by Jennifer Corbett Dooren, The Wall Street Journal
July 26th, 2007
The Food and Drug Administration will ask a panel of outside medical experts Monday whether it thinks GlaxoSmithKline PLC's diabetes drug Avandia should remain on the U.S. market.
|US: Tax Break Used by Drug Makers Failed to Add Jobs|
by Alex Berenson, The New York Times
July 24th, 2007
Two years ago, when companies received a big tax break to bring home their offshore profits, the president and Congress justified it as a one-time tax amnesty that would create American jobs.
Drug makers were the biggest beneficiaries of the amnesty program, repatriating about $100 billion in foreign profits and paying only minimal taxes. But the companies did not create many jobs in return. Instead, since 2005 the American drug industry has laid off tens of thousands of workers in thi
|US: 3 Executives Spared Prison in OxyContin Case |
by Barry Meier, The New York Times
July 20th, 2007
After hearing testimony from parents of young adults who died from overdoses involving the painkiller OxyContin, a federal judge Friday sentenced three top executives of the company that makes the narcotic to three years' probation and 400 hours each of community service in drug treatment programs.